Key statistics dashboard for TransCode Therapeutics, Inc. (RNAZ). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers.
Stock Data
| Price | $1.68 |
| Market Cap | $2M |
| Enterprise Value | -$6.0M |
| Beta | 1.50 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.03 |
| Price / Book | 0.01 |
| P/S | 0.00 |
| EV/EBITDA | 0.14 |
| EV/Sales | 0.00 |
| EV/FCF | 0.00 |
| P/FCF | -0.00 |
| Earnings Yield | -2717.35% |
| FCF Yield | -280934.18% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -58.08% |
| Return on Assets | -28.33% |
| Return on Invested Capital | -23.73% |
| Return on Capital Employed | -23.83% |
Financial Health
| Current Ratio | 1.97 |
| Quick Ratio | 1.97 |
| Cash Ratio | 1.55 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.43% |
| Net Debt / EBITDA | 0.18 |
| Interest Coverage | -5337.75 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -1.26 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 147.63 |
| Cash per share | 8.95 |
| FCF per share | -5330.50 |
| Tangible Book Value per share | -1.80 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 1.00 |
Related companies: ACXP · APRE · APVO · BOLT · GLTO · HCWB · INAB
Explore sector: Healthcare · Biotechnology
More sections of RNAZ: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks